En este momento el Servicio cuenta con los siguientes ensayos clínicos en marcha:

  • DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma. Investigador principal, Dr. Alberto Velasco. Subinvestigadora: Dra. Belén Rosado.
  • DREAMM 8: A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) in Combination with Pomalidomide and Low-Dose Dexamethasone (belantamab mafodotin - Pd) versus Pomalidomide plus Bortezomib and Low-Dose Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (Ibrutinib plus Bortezomib and Dexamtehasone in patients with R or R/R Multyple Myeloma). Investigador principal: Dr. Alberto Velasco. Subinvestigadora: Dra. Belén Rosado.
  • GEM21menos65: A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D. Investigador principal: Dr. Alberto Velasco. Subinvestigadora: Dra. Marina Menéndez.

Docencia: Hematología. Alumnos de 4º curso de Medicina de la Universidad Rey Juan Carlos.